It’s reporting season for ASX New Zealand companies! But which stock will be the most interesting to watch?
ASX New Zealand companies are amidst reporting season right now.
Although most companies use either the calendar year or July 1-June 30 financial year, ASX New Zealand companies can use the Kiwi financial year instead and this is April 1-March 31. They are still bound by the deadline to issue full year results within 2 months of the end of their financial year, so there are 2 more weeks for them to report.
Need solid trading & investment ideas on ASX?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Which ASX New Zealand companies should you look out for?
Here’s a full list of NZX listed companies and their reporting dates – some of which are listed on the ASX, others are not.
Some of the key companies to watch out for are:
- Renewable energy firm Infratil (ASX:IFT), reporting this coming Monday (May 22),
- Tower Insurance (ASX:TWR), which is reporting next Thursday (May 25), and
- Fisher and Paykel (ASX:FPH) which is unveiling its results next Friday (May 26).
The most exciting ASX New Zealand company of all
But the biggest to watch is a company you won’t find on that list of NZX-listed companies, because it is only on the ASX. Namely, SME software company Xero (ASX:XRO), which is set report on 18 May.
Consensus estimates call for NZ$1.4bn in revenue (up 27%), $277.1m in EBITDA (up 31%) and $0.06 EPS (a turnaround from a negative 6c per share in FY22). The results won’t just give us insight into how Xero is performing, but how the SME sector is performing too. And this could be telling for plenty of other ASX companies that will report in August.
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
There’s no credit card needed – the trial expires automatically.

Blog Categories
Get Our Top 5 ASX Stocks for FY26
Recent Posts
Mesoblast (ASX:MSB) Reaches Multi-Year High as Ryoncil Revenue Targets US$30M: Is It Still a Buy?
Commercial momentum builds as Mesoblast targets two major 2026 catalysts: Adult label expansion and Revascor BLA filing. Mesoblast (ASX: MSB)…
TechnologyOne (ASX: TNE) Wins $54.7M Legal Battle: Is the 34% Dip Now a Buying Opportunity?
TechnologyOne (ASX: TNE) has finally put one of Australia’s longest-running employment disputes behind it. The Federal Court threw out a…
Austal (ASX: ASB) Secures A$1bn Defence Win: A Defensive Buy at 28x Earnings?
Austal (ASX: ASB) locked in more than A$1.16 billion in new contracts last week, cementing its position as Australia’s go-to…